Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3003683 | 0.93 | CTSS (0.48) | CTSSRAB9ANPC1ARSMN1; SMN2 | |
| SCHEMBL3015833 | 0.90 | SMN1; SMN2 (0.53) | CTSSRAB9ANPC1ARSMN1; SMN2 | |
| SCHEMBL3009173 | 0.90 | MEN1 (0.52) | CTSSRAB9ANPC1ARSMN1; SMN2 | |
| SCHEMBL3018945 | 0.89 | CTSS (0.49) | CTSSRAB9ANPC1ARSMN1; SMN2 | |
| SCHEMBL3010184 | 0.89 | CTSS (0.47) | CTSSRAB9ANPC1ARSMN1; SMN2 | |
| SCHEMBL3009618 | 0.89 | MAPT (0.55) | CTSSSMN1; SMN2MEN1LMNAMAPK1 | |
| SCHEMBL3013173 | 0.86 | AR (0.53) | CTSSRAB9ANPC1ARSMN1; SMN2 | |
| SCHEMBL3013619 | 0.86 | CTSS (0.47) | CTSSRAB9ANPC1ARSMN1; SMN2 | |
| SCHEMBL3011457 | 0.86 | CTSS (0.48) | CTSSRAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL3006509 | 0.86 | SMN1; SMN2 (0.46) | CTSSRAB9ANPC1ARSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | CTSS 106/4885RAB9A 2943/4885NPC1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.